Prostate cancer: Therapeutic patent review

Expert Opinion on Therapeutic Patents

Volumn 10, Issue 12, 2000, Pages 1833-1842

  Sepp Lorenzino, L ^a   Slovin, S ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Hormonal therapy; LHRH antagonists; Prostate cancer; Targeted therapy

Indexed keywords

ABARELIX; ABARELIX DEPOT; ANTINEOPLASTIC AGENT; BICALUTAMIDE; CANCER VACCINE; CETRORELIX; CYPROTERONE ACETATE; DESLORELIN; DOCETAXEL; ESTRAMUSTINE; ETOPOSIDE; FLUTAMIDE; GONADORELIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; HISTRELIN; ITURELIX; LEUPRORELIN; LUTEINIZING HORMONE; METERLIN; NAFARELIN; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; RECIRELIN; SAMARIUM 153; STRONTIUM 89; TEVERELIX; TRIPTORELIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE;

ADULT; AFFECTIVE NEUROSIS; AGED; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER INHIBITION; CANCER MORTALITY; CANCER SCREENING; CAUSE OF DEATH; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG SYNTHESIS; DRUG TARGETING; EARLY DIAGNOSIS; GYNECOMASTIA; HORMONE INHIBITION; HOT FLUSH; HUMAN; IMPOTENCE; INCONTINENCE; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; OSTEOPOROSIS; PATENT; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; TREATMENT OUTCOME; UNITED STATES; VACCINE PRODUCTION;

EID: 0033669854     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.10.12.1833     Document Type: Review

References (75)

1. Cancer statistics, 1999
2. Advances in the application of prostate-specific antigen in the detection of early-stage prostate cancer
3. Management of advanced prostate cancer
4. Future prospects in prostate cancer
5. Comparison of perspectives on prostate cancer: Analyses of survey data
6. Biopsychosocial aspects of prostate cancer
7. The natural history, skeletal complications and management of bone metastases in patients with prostate carcinoma
8. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer
9. Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases
10. Cellular and molecular mechanisms of action of bisphosphonates
11. Bisphosphonates in the management of prostate carcinoma metastatic to the skeleton
12. The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases
13. Apoptosis: Translating theory to therapy for prostate cancer
14. Prostate cancer: Molecular biology of early progression to androgen independence
15. Science behind total androgen blockade: From gene to combination therapy
16. Studies on prostatic cancer. I. The effects of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate
17. Intermittent androgen deprivation in prostate cancer patients: Factors predictive of prolonged time off therapy
18. Hormone therapy for patients with prostate carcinoma
19. Hormonal therapy in the management of prostate cancer: An historical overview
20. Arguments against the long-term use of combined androgen blockade
21. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: A prospective randomized study
22. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer
23. Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?
24. Steroidal antiandrogens and 5alpha-reductase inhibitors
25. Androgen receptor antagonists (antiandrogens): Structure-activity relationships
26. Single-therapy androgen suppression in men with advanced prostate cancer: A systematic review and meta-analysis
27. Lutcinizing hormone-releasing hormone analogs: Their impact on the control of tumorigenesis
28. Chemotherapy for prostatic carcinoma
29. Development of GnRH antagonists for prostate cancer: New approaches to treatment
30. Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia
31. Antide and related antagonists of luteinizing hormone release with long action and oral activity
32. New, highly active antagonists of LHRH with acylated lysine and p-aminophenylalanine in positions 5 and 6
33. The LHRH antagonist cetrorelix: A review
34. Abarelix-depot (A-D) versus leuprolide acetate (L) for prostate cancer: Results of a multi-institutional, randomized, Phase III study in 271 patients
35. Effects of LHRH analogues on mitogenic signal transduction in cancer cells
36. Luteinizing hormone-releasing hormone agonists interfere with the mitogenic activity of the insulin-like growth factor system in androgen-independent prostate cancer cells
37. New effective gonadotropin releasing hormone antagonists with minimal potency for histamine release in vitro
38. Clinical trials in relapsed prostate cancer: Defining the target
39. Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm
40. Prostate specific antigen decline after antiandrogen withdrawal: The flutamide withdrawal syndrome
41. Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance
42. Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer
43. Hormone and antihormone withdrawal: Implications for the management of androgen-independent prostate cancer
44. The antiandrogen withdrawal syndrome in relapsed prostate cancer
45. The role of the androgen receptor in the development and progression of prostate cancer
46. Significance of the cag repeat polymorphism of the androgen receptor gene in prostate cancer progression
47. Ligand-independent activation of the androgen receptor in prostate cancer by growth factors and cytokines
48. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor
49. Fluorescence in situ hybridization evaluation of c-myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients
50. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells
51. Prostate cancer: Molecular biology of early progression to androgen independence
52. Androgen receptor gene mutations in hormone-refractory prostate cancer
53. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer
54. Clinical states in prostate cancer: Toward a dynamic model of disease progression
55. The Phase II/III transition. Toward the proof of efficacy in cancer clinical trials
56. Chemotherapy for patients with advanced prostate carcinoma: A new option for therapy
57. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study
58. Treatment of cancer with radiation and drugs
59. Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy
60. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases
61. Prostate-specific membrane antigen: Much more than a prostate cancer marker
62. Prostate-specific membrane antigen (PSMA): Current benefits and future value
63. Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers
64. Prostate-specific membrane antigen is produced in tumor-associated neovasculature
65. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm. PSMA expression in tumor-associated neovasculature
66. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium
67. Enzymatic activation of prodrugs by prostate-specific antigen: Targeted therapy for metastatic prostate cancer
68. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
69. Insulin-like growth factor 1 (IGF-1), IGF-1 density and IGF-1/PSA ratio for prostate cancer detection
70. Growth regulation of prostatic stromal cells by prostate-specific antigen
71. Rising PSAs after primary therapy: Active or passive intervention
72. Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man
73. Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients
74. The evolving role of dendritic cell therapy in urologic oncology